Beta-catenin destruction complex (BCDC)

The Beta-catenin destruction complex is a multi-protein assembly that serves as the central negative regulator of the canonical Wnt signaling pathway. It is composed of the scaffolding proteins Adenomatous Polyposis Coli (APC) and Axin, along with the kinases Casein Kinase 1 (CK1) and Glycogen Synthase Kinase 3 beta (GSK3B) [PMID: 23250860]. In the absence of Wnt ligands, the complex binds cytoplasmic beta-catenin, facilitating its sequential phosphorylation by CK1 and GSK3B, which triggers its ubiquitination and subsequent degradation by the 26S proteasome [PMID: 17548028]. This process maintains low levels of beta-catenin, preventing its translocation to the nucleus where it would otherwise activate pro-proliferative and oncogenic gene programs. Loss-of-function mutations in complex components, most notably APC, are hallmark drivers of colorectal cancer and other malignancies, leading to constitutive Wnt pathway activation [PMID: 22542152]. Therapeutic efforts to target this complex primarily focus on stabilizing its components, such as using Tankyrase inhibitors to prevent Axin degradation, thereby restoring the complex's ability to degrade beta-catenin in cancerous cells [PMID: 19759537].

Other names

Wnt destruction complexAPC/AXIN/GSK3B/CK1 complexBeta-catenin degradation complex

Stabilization of the destruction complex components, particularly Axin, through the inhibition of Tankyrases (TNKS1/2), which prevents the poly-ADP-ribosylation and subsequent proteasomal degradation of Axin, thereby enhancing the complex's ability to phosphorylate and degrade beta-catenin [PMID: 19759537].